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Alzheimer’s disease (AD) is a tragic, progressive, age-related neurological dysfunction, rep-
resenting one of the most prevalent neurodegenerative disorders in industrialized societies.
Globally, 5 million new cases of AD are diagnosed annually, with one new AD case being
reported every 7 s. Most recently there has been a surge in the study of the regulatory
mechanisms of the AD process, and the particular significance of small non-coding ∼22
ribonucleotide RNAs called micro RNAs (miRNAs). Abundant data have profiled miRNA
patterns in healthy, aging brain, in mild cognitive impairment (MCI), and in the moderate-
and late-stages of AD. The major mode of action of miRNA is to interact, via base-pair
complementarity, with ribonucleotides located within the 3′ untranslated region (3′-UTR)
of multiple target messenger RNAs (mRNAs), and in doing so decrease the capability of
that specific mRNA to be expressed. Many miRNAs are highly cell- and tissue-specific.The
human brain appears to use only a highly specific fraction of all known human miRNAs,
whose speciation and complexity are defined as a discrete subset of all known small non-
coding RNAs (sncRNAs) in the brain. In general, in contrast to normally, aging human brain,
in AD a family of pathogenically up-regulated miRNAs appear to be down-regulating the
expression certain brain-essential mRNA targets, including key regulatory genes involved
interactively in neuroinflammation, synaptogenesis, neurotrophic functions, and amyloido-
genesis. These up-regulated, NF-kB-sensitive miRNAs, involved in the innate immune and
inflammatory response and synaptic, neurotrophic, and amyloidogenic functions include
miRNA-9, miRNA-125b, miRNA-146a, and miRNA-155. Other miRNAs of the miRNA-15/107
family, miRNA-153 and miRNA-190, and others, will be discussed. Overall, this manuscript
will review the known contribution of miRNAs to aging brain function and the role they
appear to play in the incidence and progression of AD.
Keywords: aging, Alzheimer’s disease, amyloidogenesis, inflammation, miRNA, neurotrophism, presenilin,
synaptogenesis
INTRODUCTION
Alzheimer’s disease (AD) represents the most common type of
intellectual impairment and memory loss of the aged, character-
ized by the progressive erosion of cognition, functional ability,
coordination, mood, behavior, and memory (Alzheimer et al.,
1995; Alzheimer Association, 2012). As AD advances, a lifetime
of learning, skills and memory is progressively lost. At the one
hundred sixth anniversary of Alois Alzheimer’s (1864–1915) first
description of AD (in 1906), a tremendous amount of scien-
tific research effort into this common neurological disorder has
been obtained, however many problematic gaps in our knowledge
still remain. The increasing life expectancy and demographics of
our aging population cast significant healthcare concerns over the
future management of this leading cause of intellectual loss and
cognitive decline. There are currently no curative nor effective
clinical treatments for AD, and pharmacological strategies directed
at AD symptoms, and specifically targeted to the insidious, pro-
gressive, and inflammatory nature this brain degeneration, have
met with extremely disappointing results (Lukiw, 2007a, 2008,
2012a; Vellas et al., 2007; Fisher Center for Alzheimer’s Research
Foundation, 2011). In this second century of AD research, more
objective study, novel research investigations and interpretations
and alternative mechanistic hypotheses are clearly required to
more successfully address this complex and expanding health care
concern. This review deals with novel observations of micro RNA
(miRNA), a relatively recently described epigenetic regulatory con-
trol mechanism, on shaping the gene expression patterns in AD
brain versus healthy age-matched controls.
HUMAN microRNA
Micro RNAs represent a class of short regulatory RNAs, which
may promote sequence-dependent degradation of target mes-
senger RNAs (mRNAs) or suppress translation of corresponding
protein. The role of miRNAs in many fundamental functions
including neurodevelopment, plasticity, and apoptosis as well as
in psychiatric disease has been reported (Kosik and Krichevsky,
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2005; Bredy et al., 2011). Mature ∼19–24 nucleotide (nt) RNAs
are derived from longer miRNA precursor molecules – primary
miRNA transcript (pri-miR) ∼70–100 nt with a stem loop struc-
ture. The pri-miR is cleaved within the nucleus by a protein
complex called Drosha into a pre-miR, which is then shuttled
to the cytoplasm by the Exportin-5 pathway. In the cytoplasm,
the pre-miRNA is cleaved into mature miRNA with 3′ overhangs
by the Dicer endonuclease. One of the two strands of miRNA
in the RISC complex binds to the 3′-UTR of target mRNAs in
a sequence-dependent manner, resulting in posttranscriptional
silencing by translational repression or/and mRNA degradation
(Figure 1) miRNAs have been shown to form heteroduplexes not
only with the 3′-UTR but also with protein-coding regions as well
as the 5′-UTR (Orom et al., 2008; Tay et al., 2008).
The biological role of miRNAs has previously been reported in
multiple diseases, including AD, and in the last several years studies
have shown several miRNAs to be either up- or down-regulated in
AD, as well as their ability to regulate several important AD genes.
ALZHEIMER’S DISEASE – AN EXPANDING HEALTHCARE
CONCERN
An estimated 5.4 million people in the United States have AD,
and healthcare treatment for AD patients in the United States
currently involves a staggering 15 million unpaid caregivers and
183 billion dollars in annual costs (Alzheimer Association, 2012).
The projected yearly expense of AD healthcare is estimated to
soar to 1.1 trillion dollars by the year 2050 (Lukiw, 2007a, 2008,
2012a,b; Fisher Center for Alzheimer’s Research Foundation, 2011;
Alzheimer Association, 2012). Currently, this places a tremendous
socioeconomic burden on both AD caregivers and an already
strained healthcare system. In the foreseeable future the prog-
nosis for AD incidence and soaring medical costs become even
more stark and overwhelming and in the next 10 years will out-
strip our economic and healthcare capacity to deal with this disease
(Lukiw, 2007a, 2008, 2012a; Fisher Center for Alzheimer’s Research
Foundation, 2011; Alzheimer Association, 2012). Importantly, our
increasing life expectancy and the demographics of our aging pop-
ulation, both domestically and on a global scale, cast significant
concerns over our medical and socioeconomic capability to effec-
tively manage this rapidly expanding neurodegenerative disease.
Currently, there are no adequate preventive or curative treatments
for this leading cause of senile dementia, and pharmacological
strategies and treatments directed at AD symptoms, and specifi-
cally targeted to neurotransmitter deficits, amyloidogenesis, and
the progressively inflammatory nature of this brain degenera-
tion, have collectively met with extremely disappointing results
(Alzheimer et al., 1995; Hardy, 2006; Lukiw, 2007a, 2008, 2012a;
Fisher Center for Alzheimer’s Research Foundation, 2011; Karran
et al., 2011; Alzheimer Association, 2012).
BRAIN miRNA, EVOLUTIONARY CONSIDERATIONS, AND
RIBONUCLEOTIDE SEQUENCE SELECTION FOR HUMAN
BRAIN miRNA
As is the case for mRNAs, micro RNAs (miRs, miRNAs) are
highly developmental stage-, age-, cell-, and tissue-specific. Inter-
estingly, the human brain only uses a highly specific fraction of all
known human miRNAs, and of the ∼2000 or so human miRNAs
identified to date, the most abundant miRNAs in the human
brain probably number less than 40 (Table 1). These 40 promi-
nent species are highly expressed in the human brain and these
appear to be highly critical to the regulation of normal, homeosta-
tic brain cell functions. Again, as is the case for mRNAs, astroglial,
microglial, neuronal, and other brain cell types each appear to have
a different repertoire of miRNA (Sethi and Lukiw, 2009; Li et al.,
2012; Table 1).
Oligonucleotide and bioinformatics sequence analysis indicates
that a 22 nt single stranded small non-coding RNAs (sncRNAs),
which is the average size of a typical brain miRNA and composed
of four different ribonucleotides, could have over 1013 possible
sequence combinations, so the fact that there typically much less
than about 102 brain-abundant miRNAs suggests a very high
developmental and evolutionary selection pressure to utilize only
very specific ribonucleotide sequences that will yield biologically
useful miRNA-mRNA interactions. As fore-mentioned, miRNAs
are highly tissue- and cell-specific, even in adjacent brain cell types
(Burmistrova et al., 2007; Pogue et al., 2009; Wang et al., 2010;
Arroyo et al., 2011; Madathil et al., 2011). The small size of miRNAs
and the identification of miRNA binding proteins that prolong
naked miRNA half-life may provide a novel means of regula-
tory mechanisms “genetic signal storage” or “epigenetic memory”
(Pogue et al., 2009; Wang et al., 2010; Arroyo et al., 2011; Madathil
et al., 2011). Moreover, the recent discovery of miRNA-containing
micro-vesicles further suggests that miRNAs may provide a novel
means for paracrine and related forms of inter-cellular, inter-
tissue, and perhaps even systemic communication (Wang et al.,
2010; Arroyo et al., 2011; Chen et al., 2012; Chen et al., unpublished
observations; Vickers and Remaley, 2012). Indeed several extracel-
lular miRNAs have been found to be uniquely stable in plasma, and
lipid-based miRNA carriers, in the form of vesicles and lipoprotein
particles may be transferred to recipient cells in a paracrine fash-
ion with gene expression changes as a novel form of inter-cellular
communication (Chen et al., 2012; Lukiw et al., 2012a,b; Vickers
and Remaley, 2012). As for other nuclear transcribed genes, the
expression of a cell’s miRNA inventory appears to be regulated
by multiple transcription factors, are transcribed as pre-miRNAs,
and are not only under the transcriptional control of DNA binding
proteins, transcription factors, and RNA polymerase II (RNAPII)
and RNAPIII enzymes but further by miRNA-modifying enzymes
in the nucleus and cytoplasm that include DGCR8, Exportin-5,
Drosha, Dicer, Argonaute, and others (Figure 1; Zhao et al., 2006;
Pogue et al., 2009; Wang et al., 2010; Arroyo et al., 2011; Madathil
et al., 2011; Chen et al., 2012; Lukiw, 2012b; Vickers and Remaley,
2012).
HALF-LIFE AND STABILITY OF miRNA – EFFECTS OF HUMAN
POST-MORTEM INTERVAL AND TOTAL RNA QUALITY
Alzheimer’s disease is uniquely a disease of the human neocortex
and occurs in no other mammal or non-human primate. Although
amyloid over-expressing transgenic-AD (Tg-AD) murine models
are informative, no adequate Tg-AD animal model currently exists
that recapitulates all features of AD (Oakley et al., 2006; Ashe
and Zahs, 2010; Philipson et al., 2010; Alexandrov et al., 2011;
Li et al., 2011a,b). Analysis of miRNA array and Northern-blot-
based tracking of specific miRNA abundances and decay kinetics
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FIGURE 1 | Predicted miRNA processing pathways – APP translation and
amyloid beta generation may potentially be directly regulated by
brain-specific miRNA-153 family. Primary miRNA-153-1 and miRNA-153-2
transcripts (pri-miR) produced by RNA polymerase II, is then cleaved by the
Drosha complex in the nucleus. The resulting hairpins pre-miR-153-1 and
pre-miR-153-2 are transferred by Exportin-5 to the cytoplasm, were the
Dicer-complex generates the mature biologically active miR-153. The one
strand of the miR-153 in the RISC complex (RNA-induced silencing complex)
represses APP translation through APP 3′-UTR mRNA cleavage, whereas the
other miRNA strand is degraded. Decreasing of miR-153 levels may lead to
increased APP expression (Long et al., 2012) and further amyloid beta
production.
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Table 1 | miRNA abundance in the human neocortex – top 80 most
abundant miRNAs in control temporal lobe association neocortex
(N =18); this group was comprised of a pool of nine males and nine
females, mean age 73±7.1 years; post-mortem interval (PMI) of 3 h or
less; relative mean abundance as detected by the human MRA-1001
miRNA microfluidic chip analytical platform and giving a raw relative
signal yield of ≥2.6 (LC Sciences, Houston,TX, USA).
Micro RNA (miRNA; miR) Relative abundance
hsa-miR-125b-5p 36.6
hsa-miR-26a-5p 30.1
hsa-miR-1273g-3p 28.1
hsa-miR-4324 24.1
hsa-miR-9-3p 24.1
hsa-let-7a-5p 23.5
hsa-miR-9-5p 21.2
hsa-let-7f-5p 20.2
hsa-miR-100-5p 19.6
hsa-miR-26b-5p 19.6
hsa-let-7d-5p 18.4
hsa-let-7c 18.1
hsa-miR-3665 17.8
hsa-miR-29a-3p 17.6
hsa-miR-23b-3p 17.5
hsa-let-7e-5p 15.7
hsa-miR-23a-3p 15.7
hsa-miR-29c-3p 15.2
hsa-miR-128 15.1
hsa-miR-3960 15.0
hsa-miR-125a-5p 14.5
hsa-miR-30b-5p 14.3
hsa-let-7b-5p 14.2
hsa-let-7g-5p 14.2
hsa-let-1185-2-3p 14.1
hsa-miR-4454 13.9
hsa-miR-30c-5p 13.7
hsa-miR-221-3p 12.6
hsa-miR-99a-5p 12.6
hsa-miR-218-5p 12.0
hsa-miR-181a-5p 11.6
hsa-miR-222-3p 11.4
hsa-let-7i-5p 10.8
hsa-miR-23c 10.3
hsa-miR-29b-3p 10.3
hsa-miR-27b-3p 10.2
hsa-miR-27a-3p 9.0
hsa-miR-4787-5p 8.6
hsa-miR-137 8.6
hsa-miR-451a 8.5
hsa-miR-103a-3p 8.4
hsa-miR-107 8.0
hsa-miR-191-5p 7.9
hsa-miR-21-5p 7.9
hsa-miR-151a-5p 7.8
hsa-miR-145-5p 7.7
(Continued)
Table 1 | Continued
Micro RNA (miRNA; miR) Relative abundance
hsa-miR-151b 7.5
hsa-miR-1915-3p 7.5
hsa-miR-4516 7.5
hsa-miR-124-3p 7.4
hsa-miR-3141 7.3
hsa-miR-99b-5p 7.2
hsa-miR-338-3p 7.1
hsa-miR-195-5p 7.1
hsa-miR-139-5p 6.9
hsa-miR-181b-5p 6.8
hsa-miR-126-3p 6.6
hsa-miR-30a-5p 6.5
hsa-miR-16-5p 6.4
hsa-miR-342-3p 6.3
hsa-miR-5001-5p 6.3
hsa-miR-181d 6.3
hsa-miR-2861 6.1
hsa-miR-30d-5p 5.8
hsa-miR-5100 5.3
hsa-miR-24-3p 5.3
hsa-miR-574-3p 5.2
hsa-miR-638 4.6
hsa-miR-4530 4.3
hsa-miR-4284 4.2
hsa-miR-335-5p 4.1
hsa-miR-92a-3p 4.1
hsa-miR-7-5p 3.6
hsa-miR-361-5p 3.5
hsa-miR-466 3.5
hsa-miR-487b 3.3
hsa-miR-30e-5p 3.1
hsa-miR-101-3p 2.7
hsa-miR-3656 2.6
hsa-miR-3196 2.6
hsa-miR-34a 2.5
hsa-miR-155-5p 1.8*
hsa-miR-146a-5p 0.45*
*hsa-miR-146a and hsa-miR-155 are of relatively low basal abundance in control
association neocortex but have been observed to be induced ∼3–25 fold in AD
brain (Cui et al., 2010b; Lukiw et al., 2010; Lukiw, 2012a; Lukiw, unpublished obser-
vations).
It should be kept in mind that the evolutionary significance and relevance, if any,
of these brain neocortex-abundant miRNAs still needs to be determined, prefer-
ably in large, well controlled sample sets. Further, the relative abundance of these
miRNAs in other brain anatomical areas, and other factors such as gender effects,
individual genotype, and clinical backgrounds, including drug histories, still await
to be determined.
in human neuronal-glial cells in primary co-culture and in short
post-mortem interval (PMI, ∼1 h) human brain tissues reveals
a limited stability and relatively short half-life for many brain-
enriched miRNAs of 3 h or less (Lukiw et al., 1992; Lukiw, 2007b;
Sethi and Lukiw, 2009; Cui et al., 2010a; Rüegger and Großhans,
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2012; Zhang et al., 2012). The relatively high content of A+U
ribonucleotides, AU and UA dinucleotide sequences, and small
size in these sncRNAs further support the idea that miRNAs are
relatively unstable signaling molecules (Sethi and Lukiw, 2009;
Lukiw, 2012b; Rüegger and Großhans, 2012; Zhang et al., 2012).
AU-rich elements (AREs) are known predictors of mRNA half-life
and, analogous to mRNA stabilities, there appears to be a signifi-
cant correlation between the rate of miRNA decay and AU+UA
dinucleotide content of brain miRNA (r2∼ 0.95, N = 72; Chen
and Shyu, 1995; Mattick and Makunin, 2005; Mehler and Mattick,
2007; Sethi and Lukiw, 2009). These data therefore suggest that
miRNAs may be part of a relatively rapidly deployed signaling
system with half-lives (T1/2) on the order of minutes-to-hours.
However these observations should be interpreted with caution as
ribonucleotide sequence-specific miRNA binding proteins might
be expected to interact with and protect mature miRNAs from
impending nucleolytic attack, thus extending their half-lives and
adding yet another layer of complexity to miRNA-mediated gene
regulation. To date all cumulative data suggests that unless specif-
ically stabilized, certain brain-enriched miRNAs represent a rela-
tively rapidly executed signaling system employing highly transient
effectors of central nervous system (CNS) gene expression (Sethi
and Lukiw, 2009; Rüegger and Großhans, 2012; Zhang et al., 2012).
In past and ongoing studies we have therefore focused only on the
analysis of up-regulated miRNAs as down-regulation of miRNA
abundance may be, in part, a consequence of their relatively short
half-life, and uncontrolled and rapid degradation, especially in
human post-mortem tissues with difficult-to-control variability in
agonal processes and related effects of dying human brain tissues
on biomolecular integrity (Figure 2; Chen and Shyu, 1995; Lukiw
et al., 1998, 2012b; Cui et al., 2005; Mattick and Makunin, 2005;
Mehler and Mattick, 2007; Sethi and Lukiw, 2009; Lukiw, 2012b;
Lukiw and Alexandrov, 2012; Rüegger and Großhans, 2012; Zhang
et al., 2012).
micro RNA – AN OVERVIEW OF A NOVEL REGULATORY
MECHANISM
As fore-mentioned, robust miRNA-mediated regulation of mRNA
complexity in the human CNS is emerging as a critical factor
in regulating CNS-specific gene expression during development,
plasticity, aging, and age-related neurological disease. As a part of
a large and diverse single stranded RNA family in the cell, miRNAs
constitute an evolutionarily conserved group sncRNA molecules,
and as such represent a recently discovered family of labile, het-
erogeneous, regulatory sncRNAs (Ambros, 2004; Guo et al., 2010;
Taft et al., 2010; Li et al., 2011b). The most prevalent mode
of action of miRNAs is the recognition, via base-pair comple-
mentarity, with the 3′ untranslated regions (3′-UTRs) of specific
mRNA targets (Ambros, 2004; Guo et al., 2010). Depending on 3′-
UTR sequence complementarity within the RNA-induced silenc-
ing RISC complex, productive miRNA-mRNA interaction results
in either reduction or inhibition in the translational efficiency of
the target mRNA. Hence a major miRNA-mediated gene control
mechanism is that up-regulated miRNAs repress the expression
from their mRNA targets (Lukiw et al., 1992; Ambros, 2004; Per-
ron and Provost, 2009; Guo et al., 2010; Taft et al., 2010; Lukiw,
2012b). Indeed ribosome profiling experiments have indicated
FIGURE 2 | miRNA stability – (A) RNA integrity number (RIN) versus
post-mortem interval (PMI); the correlation of RNA integrity to a
positive RIN number is statistically highly significant (r 2∼0.95;
N =72); (B) Half-life of several selected miRNAs; the content, position
and 5′–3′orientation of A and U ribonucleotides, and AU-rich elements
(AREs) appears to affect miRNA stability, with half-lives generally in
the range of 1–7 h (see Sethi and Lukiw, 2009; Rüegger and Großhans,
2012; Zhang et al., 2012).
that mammalian miRNAs predominantly act to decrease the abun-
dance of their target mRNA levels, and in doing so quench specific
mRNA transcription to down-regulate expression of that gene
(Ambros, 2004; Guo et al., 2010). Although the potential con-
tribution of sncRNA to brain function has been known for at least
20 years (Lukiw et al., 1992), more recently there been a great deal
of effort into the molecular and genetic mechanism involving the
neurobiological and pathological functions of these miRNAs and
sncRNAs in CNS health, development, aging, and disease (Taganov
et al., 2006; Burmistrova et al., 2007; Lukiw and Pogue, 2007; Hill
et al., 2009; Perron and Provost, 2009; Pogue et al., 2009; Tsitsiou
and Lindsay, 2009; Lukiw et al., 2010; Wang et al., 2010; Arroyo
et al., 2011; Madathil et al., 2011). Overall, up-regulated brain miR-
NAs can therefore be considered a novel neuro-regulatorymechanism
that post-transcriptionally down-regulates their target mRNAs, and
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hence down-regulates selective gene expression in neural cells and
tissues. Multiple different miRNAs can bind to a single mRNA 3′-
UTR by a phenomenon known as miRNA convergence; alternately
the same single miRNA may recognize multiple mRNA 3′-UTRs by
a phenomenon known as miRNA divergence (Lukiw and Alexan-
drov, 2012). In miRNA divergence, a single miRNA has potential to
regulate the expression of a small family of potentially pathogenic
genes, as is the case for an up-regulated miRNA-125b targeting
the essential synaptic protein synapsin-2 (SYN-2),15-lipoxygenase
(15-LOX), and the cell cycle regulator CDKN2A, or miRNA-146a
targeting the innate immune system regulator complement factor
H (CFH), interleukin-1 beta associated kinase-1 (IRAK-1), and
the βAPP-membrane associated tetraspanin-12 (TSPAN12; Cui
et al., 2010a; Li et al., 2011a,b; Lukiw and Alexandrov, 2012; Lukiw
et al., 2012a,b). Hence just two up-regulated miRNAs (miRNA-
125b) and miRNA-146a can explain many of the pathogenic
effects in AD including synaptic and neurotrophic deficits (SYN-
2, 15-LOX), astrogliosis (CDKN2A), immune and inflammatory
signaling (CFH, IRAK-1), and amyloidogenesis (TSPAN12; Lukiw
and Alexandrov, 2012; Lukiw et al., 2012a,b; Figure 2). Overall,
significantly up-regulated miRNAs in neurodegenerative disorders
such as AD may help explain the large number (roughly 2/3) of all
brain gene mRNAs observed to be progressively and significantly
down-regulated in anatomical regions sensitive to the AD process
(Loring et al., 2001; Colangelo et al., 2002; Lukiw, 2004; Liang et al.,
2008; Ginsberg et al., 2012).
Numerous miRNAs such as members of miR-15/107 family
have ribonucleotide sequence similarity, and therefore have related
target mRNAs (Finnerty et al., 2010). Recent studies indicate a pos-
sible role for miR-107 in AD pathology. miR-107 is exceptional
example of miRNA related to AD, because it has been shown that
expression level of the miR-107 can change in brains of AD patients
even in the earlier stages of disease (Wang et al., 2008). Moreover
miR-107 has a target site in 3′-UTR of β-amyloid cleavage enzyme
1 (BACE1) mRNA which is the first enzyme in the amyloido-
genic pathway of amyloid precursor protein (APP) processing.
miR-107 is enriched in neurons and recent studies indicate that
numerous members of miR-15/107 family having the target sites in
BACE1 gene including miR-15a, miR-15b, mR-16, miR-195, miR-
103 as well as miR-107; all of these miRNAs are down-regulated
in gray matter of AD patients (Wang et al., 2011). Other studies
have shown that miR-29a, miR-29b-1, and miR-9 can decrease
the expression of BACE1 (Hebert et al., 2008; Vassar et al., 2009;
Shioya et al., 2010). Altogether these data indicate that different
miRNAs change the BACE1 expression level and thus contribute
to AD pathology (Figures 2 and 3).
HUMAN BRAIN-ABUNDANT miRNAs
Utilization of the most advanced MRA-1001 miRNA microfluidic
chip analytical platform currently available (LC Sciences, Hous-
ton, TX, USA), about 2000 individual human miRNAs have been
identified to date in human cells and tissues. As fore-mentioned,
not all of these are present in the brain or in CNS tissues, and the
number of most abundant miRNAs in the human brain neocor-
tex number is about 40 (Table 1; Burmistrova et al., 2007; Lukiw,
2012b; Lukiw, unpublished observations). Data in Table 1 were
obtained from human brain tissue samples of 3 h or less and were
compared to age-matched controls in the same brain anatomical
region that is targeted by AD. Although we cannot exclude the
contribution to AD pathology of other human brain miRNAs,
the inducible, NF-kB-regulated miRNAs miRNA-9, miRNA-125b,
miRNA-146a, and miRNA-155 show some of the most signif-
icant up-regulated changes in all AD brains so far examined
(N = 72; Lukiw et al., 2008; Cui et al., 2010a; Lukiw, 2012b).
The following section gives further structural and functional
details on these inducible miRNAs – including miRNA-9, miRNA-
125b, miRNA-146a, and miRNA-155 – that have been shown to
be up-regulated in short PMI Alzheimer hippocampus and/or
neocortex.
UP-REGULATED NF-κB-SENSITIVE miRNAs IN AD
NEOCORTEX, HIPPOCAMPUS, AND IN AGE-RELATED
MACULAR DEGENERATION AFFECTED RETINA
miRNA-9
The 23 oligonucleotide human miRNA-9 (GenBank NR_029691.1;
chr 1q22) is an NF-kB-regulated, retinoic acid-inducible sncRNA
enriched in primary human neural cells (a neuronal-glial cell pri-
mary co-culture), in cultured human NTera-2 clone D1 cells and in
human ARPE-19 cells (Sempere et al., 2004; Du and Zamore, 2005;
Singh, 2007; Singh, unpublished observations; Williams et al.,
2008; Sethi and Lukiw, 2009). In multiple independent studies
miRNA-9 has been associated with neurogenesis, morphogenesis,
developmental patterning, brain cell proliferation, and glioblas-
toma (Sempere et al., 2004; Singh, 2007; Bazzoni et al., 2009;
Hébert and De Strooper, 2009; Tsitsiou and Lindsay, 2009; Arora
et al., 2010; Kutty et al., 2010a,b; Zhang et al., 2010; Bonev et al.,
2011; Shibata et al., 2011; Yuva-Aydemir et al., 2011). miRNA-9 is
easily detectable in both the neocortex and retina it was found to
be one of the most variably abundant miRNA in these tissues, per-
haps indicative of its highly inducible nature (Singh, 2007; Bazzoni
et al., 2009; Arora et al., 2010; Arora et al., unpublished obser-
vations; Kutty et al., 2010a,b; Shibata et al., 2011; Yuva-Aydemir
et al., 2011). Enriched in AU or UA dinucleotide content, with
a half-life of only 30–60 min in both cultured human primary
brain cells and human brain tissues, miRNA-9 is a brain and
retinal abundant miRNA possessing the shortest half-life of any
miRNA studied to date (Williams et al., 2008; Pogue et al., 2009;
Sethi and Lukiw, 2009). Interestingly, miRNA-9 exerts significant
control of neural progenitor cell proliferation and differentiation
in the developing telencephalon by regulating the expression of
multiple transcription factors including Foxg1, Nr2e1, and Pax6
(Shibata et al., 2011). We further note that miRNA-9 is develop-
mentally regulated and abundant in ARPE-19 retinal epithelial
cells, and decreases in expression as human brain and retinal cells
age in primary culture, in accordance with its established role as a
developmentally regulated miRNA (Arora et al., 2010; Kutty et al.,
2010a,b; Yuva-Aydemir et al., 2011). Knockdown of miRNA-9 in
neural progenitor cells, results in an inhibition of neurogenesis
along the anterior-posterior axis of the CNS, and miRNA-9 is also
significantly down-regulated in the tissues of fetuses with severe
congenital abnormalities, including anencephaly (Zhang et al.,
2010; Bonev et al., 2011). In a recent miRNA analysis of whole
murine globes using both microarray and RNA in situ hybridiza-
tion procedures, miRNA-9 expression was restricted to the retina
and not seen in the cornea, lens, iris, or ciliary body (Hébert and
De Strooper, 2009; Tsitsiou and Lindsay, 2009).
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FIGURE 3 | MiRNAs and their evolutionary-conserved sites in
3′-UTR-gene regions for AD genes (TargetScan prediction,
http://www.targetscan.org). Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2)
cleave Type I transmembrane proteins (including APP), whereas their distant
structural homologs IMPAS1/SPP or other IMPAS/SPPL proteases cleave Type
II transmembrane proteins. Interestingly, redundant PSEN1 and PSEN2 as
well as IMPAS1 and IMPAS2 have very different numbers of
evolutionary-conserved targets for miRNAs in 3′-UTR. MiRNA-9 that is
up-regulated in AD neocortex, hippocampus, and in age-related macular
degeneration affected retina is indicated in red. MiRNAs that are most
abundant in control temporal lobe association neocortex (seeTable 1) are
indicated in green.
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miRNA-125b
One of the most intensively studied, and human brain and
retinal abundant miRNA is the inducible miRNA-125b (Gen-
Bank NR_029671.1; chr 11q24.1; Table 1). miRNA-125 was first
shown to be up-regulated in differentiating mouse and human
neurons, and since implicated in mammalian neuronal devel-
opment and function in the brain (Madathil et al., 2011). Both
miRNA-125b and miR-9 play central roles in neuronal differ-
entiation during retinal development (Arora et al., 2010; Kutty
et al., 2010a,b; Maiorano and Hindges, 2012). The abundance
of miRNA-125b has been shown to be significantly induced by
neurotoxic metal sulfates that generate robust levels of oxida-
tive stress, and miRNA-125b is also up-regulated in brain can-
cers where it apparently targets and down-regulates CDKN2A, a
negative regulator of cell growth (Sempere et al., 2004; Lukiw,
2007a,b; Sethi and Lukiw, 2009; Pogue et al., 2010; Feng et al.,
2011). Up-regulated miRNA-125b further associates with glial
cell proliferation and astrogliosis in inflammatory neurodegen-
erative conditions such as AD and Down’s syndrome (DS), as
well as in glioma and glioblastoma multiforme (Pogue et al.,
2010; Feng et al., 2011; Lukiw et al., 2011). Up-regulation of
miRNA-125b is further associated with down-regulation of both
the 15-lipoxygenase (15-LOX) and the synaptic vesicle-associated
phosphoprotein synapsin-2 (SYN-2; Lukiw et al., 2008, 2011; Feng
et al., 2011; Pogue et al., 2011; Li et al., 2012; Lukiw and Alexan-
drov, 2012). The 15-LOX enzyme is essential in the conversion
of the essential omega-3 fatty acid docosahexaenoic acid (DHA)
into the potent neuroprotectin D1 (NPD1), and deficits in 15-
LOX correlate with NPD1 deficits in AD brain and other human
tissues (Lukiw et al., 2005; Hennig et al., 2007; Zhao et al., 2011;
Chen et al., 2012). The neuronal-enriched phosphoprotein SYN-2
that associates with the cytoplasmic surface of synaptic vesicles
is also a miRNA-125b target (Yao et al., 2003). MiRNA-125b up-
regulation is further associated with SYN-2 down-regulation in
inflammatory neuro-degeneration and CFH down-regulation in
human primary astroglial cells (Yao et al., 2003; Pogue et al.,
2010, 2011). Interestingly miRNA-125b and miRNA-146a have
tandem binding sites in the mRNA 3′-UTR of human CFH, a
key repressor of the innate and immune response in the brain;
indeed miRNA-125b and miRNA-146a appear to be involved in
immune system activation, at least in part by reducing inter-
feron regulatory factor 4 (IRF4) levels thus potentiates induction
of the immune response (Cui et al., 2010a; Chaudhuri et al.,
2011).
miRNA-146a
miRNA-146a (GenBank NR_029701; chr 5q34) was first described
as an inducible, NF-κB-regulated pro-inflammatory miRNA that
was found to target signaling proteins of innate immune responses,
and more specifically the 232 nt 3′-UTR of CFH mRNA in human
monocytes (Taganov et al., 2006, 2007; Baltimore et al., 2008;
Lu et al., 2010). More recently nt analysis of the CFH mRNA
3′-UTR indicates that the CFH mRNA 3′-UTR contains multi-
ple binding sites for miRNA-9, miRNA-125b, miRNA-146a, and
miRNA-155 including an overlapping miRNA regulatory control
(MiRC) region that contains overlapping binding sites for miRNA-
146a and miRNA-155 (Lukiw et al., 2012a,b). Interestingly the
brain and retina may use alternate miRNA binding sites in the
CFH mRNA 3′-UTR to regulate CFH expression, and this may
have a bearing on innate immune and inflammatory responses to
stress in AD or age-related macular degeneration (AMD; Lukiw
et al., 2012a,b). Elevated miRNA-146a in AD brain has been
shown to also specifically target CFH and the interleukin-1 asso-
ciated kinase-1 (IRAK-1) mRNAs, and is believed to contribute
to altered innate immune responses and neuroinflammation in
degenerating human brain cells and tissues in inflammatory neu-
rodegenerative diseases including AD, AMD, prion disease, in
experimental and human temporal lobe epilepsy, in experimen-
tal diabetes in retinal microvessel endothelial cells, and in primary
human brain cells stressed with ROS-generating metal sulfates
(Lukiw and Pogue, 2007; Lukiw et al., 2008, 2011; Pogue et al.,
2009, 2011; Aronica et al., 2010; Cui et al., 2010a; Li et al., 2011a,b,
2012; Madathil et al., 2011; Lukiw and Alexandrov,2012; Saba et al.,
2012). Although CFH was classically regarded as highly abundant
human serum protein of hepatic origin, abundant CFH presence
in brain and retinal tissues suggests CFH involvement in the innate
immune response and inflammatory regulation within the “priv-
ileged immunology” of these tissues (Lukiw, 2007a; Lukiw et al.,
2008; Ashe and Zahs, 2010; Donoso et al., 2010; Gehrs et al., 2010;
Taft et al., 2010; Zipfel et al., 2010; Deangelis et al., 2011; Fisher
Center for Alzheimer’s Research Foundation, 2011; Kondo et al.,
2011;Alzheimer Association,2012). While miRNA-146a is the least
basally abundant miRNA when compared to miRNA-9, miRNA-
125b, and miRNA-155, it is the most inducible and up-regulated
miRNA in human neuronal and astroglial cells compared to all
other NF-κB-regulated miRNA species so far indentified (Lukiw
et al., 2008, 2011; Cui et al., 2010a; Pogue et al., 2011; Lukiw,
2012a,b). Interestingly, miRNA-146a may be the most induced of
all of the up-regulated miRNAs in AD and prion brain due to the
presence of three tandem, canonical NF-κB binding sites within
the human pre-miRNA-146a promoter (Lukiw et al., 2008, 2012b).
miRNA-155
A cytokine, NF-κB, and cell cycle-regulated miRNA, miRNA-
155 (GenBank NR_030784; chr 21q21.3) is also abundant in
the human neocortex and retina, and has approximately 45%
sequence homology to miRNA-146a (O’Connell et al., 2007;
Lukiw and Alexandrov, 2012; Lukiw et al., 2012a,b). Interestingly,
miRNA-146a and miRNA-155 have partially overlapping binding
(recognition) sites in the CFH mRNA 3′-UTR, and miRNA-146a
and miRNA-155 together define an overlapping MiRC region
in the CFH 3′-untranslated region (3′-UTR; 5′-TTTAGTATTAA-
3′) herein either of these miRNAs may interact (Lukiw and
Alexandrov, 2012). As is true for miRNA-146a, inflammatory
cytokines increase miRNA-155 expression in human retinal pig-
ment epithelial cells by activation of the JAK/STAT signaling path-
way (O’Connell et al., 2007). Several additional studies indicate
that miRNA-146a and miR-155 together play a key role in reg-
ulating several critical pathways that orchestrate innate immune
responses and chronic inflammatory processes that are conserved
across many different human tissue systems; this may be a conse-
quence of their related ribonucleotide sequence (O’Connell et al.,
2007; Tsitsiou and Lindsay, 2009; Kutty et al., 2010a,b; Roy and
Sen, 2011).
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miRNA-9, miRNA-125b, miRNA-146a, AND miRNA-155 mRNA TARGETS
IN THE BRAIN
The actions of up-regulated miRNAs on down-regulating their
target mRNAs in AD is attractive in that many interwoven aspects
of AD neuropathology and progression can be explained by the
pathogenetic activities of a relatively small number of these sncR-
NAs. For example, up-regulation of the human brain-abundant
miRNA-125b is associated with down-regulation in the expres-
sion of the cyclin-dependent kinase inhibitor 2A (CDKN2A),
a miRNA-125b target, and negative regulator of astroglial cell
growth (Pogue et al., 2010). A strong positive correlation between
miRNA-125b abundance and the glial cell markers glial fibril-
lary acidic protein (GFAP) and vimentin, and CDKN2A down-
regulation is apparent in advanced AD and in DS brain; both
of these chronic neurological disorders are typified by a pro-
gressive astrogliosis (Pogue et al., 2010; Lukiw and Alexandrov,
2012). The neuronal-enriched phosphoprotein SYN-2 that asso-
ciates with the cytoplasmic surface of synaptic vesicles is also a
miRNA-125b target, and miRNA-125b up-regulation also corre-
lates with SYN-2 down-regulation in AD brain (Yao et al., 2003;
Lukiw and Alexandrov, 2012). Another miRNA-125b target is 15-
lipoxygenase (15-LOX; Lukiw et al., 2005; Hennig et al., 2007; Zhao
et al., 2011; Lukiw and Alexandrov, 2012). The 15-LOX enzyme
is essential in the conversion of the essential omega-3 fatty acid
DHA into the potent docosanoid neuroprotectin D1 (NPD1), and
deficits in 15-LOX significantly correlate with NPD1 deficits in AD
brain (Lukiw et al., 2005; Hennig et al., 2007; Zhao et al., 2011).
Hence, the actions of miRNA-125b divergence can explain three
characteristic deficits in AD brain including glial cell proliferation,
synaptic, and neurotrophic failure and other key pathophysiolog-
ical aspects of the AD process (Figure 4; Yao et al., 2003; Lukiw
et al., 2005; Hennig et al., 2007; Taganov et al., 2007; Baltimore
et al., 2008; Lu et al., 2010; Pogue et al., 2010; Chaudhuri et al.,
2011; Zhao et al., 2011; Lukiw and Alexandrov, 2012).
In line with these ideas, CFH is a key negative regulator of the
innate immune and complement system, and miRNA-9, miRNA-
146a, and miRNA-155 up-regulation is associated with decreased
CFH in the neuro-degeneration associated with AD, prion dis-
ease, and temporal lobe epilepsy (Lukiw et al., 2008; Hébert and
De Strooper, 2009; Perron and Provost, 2009; Aronica et al., 2010;
Li et al., 2010; Saba et al., 2012). An up-regulated miRNA-146a
is further associated with down-regulation of the interleukin-
1β-associated kinase-1 (IRAK-1), with a compensatory surge
in IRAK-2 that is involved in a more chronic and sustained
form of NF-kB activation that supports pro-inflammatory signal-
ing in human brain cells (Granic et al., 2009; Kaltschmidt and
Kaltschmidt, 2009; Cui et al., 2010a). Additionally, the mRNA
encoding a four-time membrane spanning integral membrane
protein tetraspanin-12 (TSPAN12) is also a target for miRNA-
146a, and up-regulated miRNA-146a further contributes to the
down-regulation of TSPAN12 as is observed in AD brain and
in cytokine and Aβ-peptide-stressed human brain cells (Junge
et al., 2009; Xu et al., 2009; Li et al., 2011a,b). Interestingly, suf-
ficient TSPAN12 appears to be required for the neurotrophic
processing of the beta-APP into a neurogenic soluble form of
beta-APP known as sAPPα; insufficient TSPAN12 is associated
with the induction of amyloidogenesis, vascular aberrations, and
FIGURE 4 | miRNA up-regulation and down-regulation of AD-relevant
gene expression; a relatively small number of up-regulated miRNAs
may impact several key pathological features of AD, including the
modulation of glial cell proliferation, synaptic and neurotrophic failure,
neuroinflammation, and amyloidogenesis.
Aβ42 peptide evolution (Junge et al., 2009; Xu et al., 2009). There-
fore, the integrated miRNA-mRNA interactions of as few as two
induced human brain miRNAs – miRNA-125b and miRNA-146a –
may in part explain not only the observed down-regulation of
CDKN2A, SYN-2, 15-LOX, CFH, IRAK-1, and TSPAN12 expres-
sion but may also contribute to pathogenic deficiencies linked
with astrogliosis, synaptogenesis, neurotrophic support, innate
immune and inflammatory signaling, and amyloidogenesis in the
core mechanism of the AD process.
POTENTIAL REVERSAL OF PATHOGENIC miRNA ACTIONS
USING ANTI-miRNA STRATEGIES
A growing body of evidence suggests that antagonizing miRNA
activity through the use of anti-miRNAs (AMs, antagomirs) may
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be a useful approach to quenching the pathogenic effects of up-
regulated miRNAs in the brain (Lukiw et al., 2008; Cui et al.,
2010a; Lukiw, 2012b). Specifically designed synthetic AMs, per-
fectly antisense to naturally occurring miRNAs, may have their
half-life extended through the use of various strategies includ-
ing locked nucleic acid (LNA) protection. LNA-modified AMs
have been shown to be highly efficacious in human brain cells in
primary culture but the implementation of these technologies in
human clinical trials awaits further development (Lukiw, 2012a).
CONCLUSION
The conservation and extreme selection of specific miRNAs
among diverse species suggests that they bear important and con-
served biological functions throughout evolution (Rogaev, 2005;
Weber, 2005; Wang et al., 2010). Indeed, accumulating data indi-
cate that miRNAs are playing an expanding role from neuro-
regeneration to neuro-degeneration in human brain development
and neurological disorders (Rogaev, 2005; Lukiw and Pogue, 2007;
Lukiw et al., 2008, 2011; Pogue et al., 2011; Li et al., 2012; Lukiw
and Alexandrov, 2012). The characterization of RNA complex-
ity in short PMI human brain tissues is highly informative, even
though miRNA stability may be a real concern in data and bioin-
formatics analysis (Lukiw et al., 1992, 1998; Cui et al., 2005, 2010a;
Lukiw, 2007b; Lukiw and Pogue, 2007; Sethi and Lukiw, 2009;
Rüegger and Großhans, 2012; Zhang et al., 2012). Interestingly,
whole nuclei isolated from human brain tissues with PMI’s of up to
3–4 h efficiently support run-on gene transcription, an effect that
is inhibited using the octapeptide RNAPII nt incorporation and
translocation inhibitor α-amanitin (Lukiw et al., 1998; Cui et al.,
2005; Lukiw and Pogue, 2007). The contribution of several brain
cell types in CNS tissues to miRNA speciation, abundance, and
complexity needs to be further addressed by analyzing individual
human brain cell types in primary cell culture, in Tg-AD models
and perhaps by using single cell amplification techniques (Pogue
et al., 2010; Li et al., 2011a,b; Ginsberg et al., 2012; Saba et al., 2012).
Analysis of miRNA in autopsied brain tissues with PMIs many-
fold greater than the half-lives of individual miRNAs may lead
to inaccurate conclusions concerning their absolute abundance,
and hence the contribution of specific miRNAs to gene regulation
in the brain during development, aging, and in disease processes
(Table 1, Figure 1). To add another layer of complexity, it should
also be noted that different brain cells from different brain regions
may have different stabilities for the same sncRNAs and miRNAs
due to initial abundance, the stabilizing effects of miRNA binding
proteins, compartmentalization, relative mean abundances, and
related intrinsic factors such as miRNA secondary and tertiary
structure and miRNA binding proteins (Lukiw et al., 1998, 2008;
Cui et al., 2005; Sethi and Lukiw, 2009; Feng and Feng, 2011; Im
and Kenny, 2012; Rüegger and Großhans, 2012; Zhang et al., 2012).
SUMMARY
Human brain miRNAs are currently acquiring essential and deter-
minant roles in advancing our understanding of the regulation of
CNS-relevant gene expression and the epigenetic regulatory mech-
anisms of aging in both health and disease (Lukiw et al., 1992, 2010,
2012b;Ambros,2004; Oakley et al., 2006; Lukiw,2007b; Perron and
Provost, 2009; Pogue et al., 2009; Sethi and Lukiw, 2009; Tsitsiou
and Lindsay, 2009; Ashe and Zahs, 2010; Cui et al., 2010a; Guo
et al., 2010; Philipson et al., 2010; Alexandrov et al., 2011; Li et al.,
2011b; Madathil et al., 2011). That approximately 85% of eukary-
otic genomes are transcribed into various kinds of RNA, and that
only about 2% of the genome is transcribed into protein, under-
scores the potential of various complex layers of RNA signaling and
RNA-based regulatory mechanisms that are known to contribute
to homeostatic gene control (Oakley et al., 2006; Taganov et al.,
2006; Lukiw, 2007a,b). It will be interesting to further research the
complimentary roles of specific transcription factors and miRNAs,
and the interactive roles of these sncRNAs in the phenomenon of
miRNA divergence and convergence, as they appear to play highly
interrelated and cooperative roles in the regulation of CNS gene
expression (Burmistrova et al., 2007; Lukiw, 2007b; Ashe and Zahs,
2010; Cui et al., 2010a; Philipson et al., 2010; Wang et al., 2010;
Arroyo et al., 2011). To cite just one example, pre-miRNA-146a,
an inducible, NF-κB-regulated gene, has been associated with the
development and propagation of prion disease, epileptogenesis,
viral infection, neuro-degeneration, and the induction of neuro-
inflammatory signaling and altered innate immune responses in
primary human neural cell culture models of AD (Lukiw, 2007b,
2008; Perron and Provost, 2009; Sethi and Lukiw, 2009; Ashe
and Zahs, 2010; Lukiw et al., 2010). It may be possible to target
these pathogenic miRNA effects in AD and related neurological
disorders using AM (antagomir) strategies, either alone or in com-
binatorial approaches (Lukiw et al., 2008, 2010; Pogue et al., 2009;
Tsitsiou and Lindsay, 2009; Cui et al., 2010a; Madathil et al., 2011).
Overall, selectively up-regulated miRNA abundances in regions of
brain targeted by AD neuropathology, that are not increased in the
same brain anatomical regions in normal aging or in other neu-
rological disorders, further implicates their selective involvement
in AD pathology and the pathogenetic and regulatory signaling
processes associated with multiple interwoven aspects of the neu-
rodegenerative disease process (Oakley et al., 2006; Taganov et al.,
2006; Lukiw, 2007b; Guo et al., 2010). A clearer understanding of
how miRNAs influence the initiation and progression of AD and
related neuropsychiatric disorders may not only reveal fundamen-
tal insights into the causes of these devastating human neurological
disorders, but should also provide novel pharmacological strate-
gies for advanced and efficacious intervention in the future clinical
management of AD (Feng and Feng, 2011; Im and Kenny, 2012;
Lukiw, 2012a; Percy et al., 2012).
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